Your session is about to expire
← Back to Search
Sofosbuvir/Velpatasvir for Heart Transplant
Study Summary
This trial is testing the safety and efficacy of transplanting hearts from HCV seropositive non-viremic and HCV seropositive viremic donors to HCV seronegative recipients. Treatment and prophylaxis will be used to prevent HCV transmission.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 4 trial • 11 Patients • NCT03235154Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does the recruitment process extend to individuals of younger ages?
"Prospective participants must be between 18 and 71 years old to qualify for this clinical trial."
Has the registration period for this trial begun?
"This medical trial, which was initially published on August 1st 2017 and last modified on November 21st 2022 is not currently enrolling patients. However, 316 other studies are actively seeking participants at this very moment."
What risks, if any, are associated with sofosbuvir/velpatasvir consumption?
"Our team at Power rated sofosbuvir/velpatasvir's safety a 2, as the drug is still in Phase 2 and has only been confirmed to be safe, but not effective."
Who is eligible to take part in this clinical experiment?
"This clinical trial is currently seeking 20 participants suffering from hepatitis c, between the ages of 18 and 71. To be eligible for consideration one must have end stage heart failure, not present any obvious contraindications to liver transplants, be willing to travel regularly to UPMC over a course of at least 12 months following transplantation and use contraception for an additional year post-surgery. Furthermore, having HCV NAT positive or negative does not impede participation in this study."
How many volunteers are partaking in this research endeavor?
"Recruitment for this clinical trial has closed, with the research being initially published on August 1st 2017 and lastly updated on November 21st 2022. For those seeking alternative studies, there are currently 289 active trials concerning hepatitis c and 27 related to sofosbuvir/velpatasvir recruiting participants."
Share this study with friends
Copy Link
Messenger